fbpx

ABOUT VHIO

VHIO is a leading comprehensive cancer center of excellence where its scientists and physicians adopt a purely translational research model, working together as multidisciplinary teams to both accelerate and advance personalized and targeted therapies against cancer:

DISCOVER MORE

PROGRAMS & GROUPS

Scientific activity at VHIO is structured across for major programs: Preclinical, Translational, Clinical Research, and Core Technologies. Each incorporates research teams of excellence dedicated to harnessing and rapidly translating discoveries into tangible benefits for patients.

MEET VHIO´S TEAMS

NEWS

Immune cells in cerebrospinal fluid: predictors of response to immunotherapy against brain metastasis

08/03/2021|Comments Off on Immune cells in cerebrospinal fluid: predictors of response to immunotherapy against brain metastasis

AACR’s Project GENIE hits another phenomenal milestone: 9th public data set now released

26/02/2021|Comments Off on AACR’s Project GENIE hits another phenomenal milestone: 9th public data set now released

Driving nano-based approaches closer to the clinic: Vall d’Hebron leads pilot study to assess the efficacy of nanoparticles against pancreatic cancer

25/02/2021|Comments Off on Driving nano-based approaches closer to the clinic: Vall d’Hebron leads pilot study to assess the efficacy of nanoparticles against pancreatic cancer

VHIO-led study unveils novel mechanism of resistance to T-cell bispecific antibodies and CAR-T targeting HER2 breast cancer

23/02/2021|Comments Off on VHIO-led study unveils novel mechanism of resistance to T-cell bispecific antibodies and CAR-T targeting HER2 breast cancer

Proof-of-concept study points to the placenta as a protective barrier against COVID-19 during pregnancy

18/02/2021|Comments Off on Proof-of-concept study points to the placenta as a protective barrier against COVID-19 during pregnancy

Expert panel discussion: latest treatment regimens, novel therapies and advances against NSCLC

12/02/2021|Comments Off on Expert panel discussion: latest treatment regimens, novel therapies and advances against NSCLC

SEE ALL NEWS

Follow us:

DIRECTION &
PRINCIPAL INVESTIGATORS

Research at VHIO is led by our Director, Josep Tabernero, and supported by a consultative body, VHIO’s Scientific Committee. A total of 26 renowned Principal Investigators manage and run VHIO’s major research themes and programs.

BROWSE OUR PIS

SCIENTIFIC
REPORT
2019

LAUNCH

CLINICAL TRIALS

Driving drug development & targeted therapies against cancer, VHIO has become a leading reference in drug discovery from concept to clinic:

CLINICAL TRIALS OFFICE
RESEARCH UNIT FOR MOLECULAR THERAPY OF CANCER (UITM) – “LA CAIXA” FOUNDATION
CURRENTLY OPEN TRIALS

PROJECTS & INSTITUTIONAL PROGRAMS

Research at VHIO is made possible through the support received from private institutions, funding entities, companies and individuals, as well as International and National Competitive Grants. Find out more about our supporters, current projects and VHIO´s Scientific Coordination Area:

CURRENT PROJECTS
FERO FOUNDATION’S ADVANCED MOLECULAR DIAGNOSTICS PROGRAM
BBVA FOUNDATION’S IMMUNOTHERAPY & IMMUNOLOGY PROGRAM (CAIMI)
“LA CAIXA” INTL RESEARCH & EDUCATION PROGRAM
SCIENTIFIC COORDINATION

EVENTS

VHIO organizes symposia of excellence and ad-hoc courses & workshops through which it shares its expertise and promotes debate and exchange of the highest degree:

VHIO – ”LA CAIXA” SCIENTIFIC SEMINARS SERIES
INTERNATIONAL SYMPOSIA
WORKSHOPS & COURSES
BENCHSTORMING SEMINARS